PRKAA2 and metabolic disease: To date, many direct or indirect activators of AMPK have been developed, and some are currently being evaluated for their contribution to human diseases and disorders (mostly metabolic diseases, inflammation-associated diseases, and cancers; Steinberg and Carling, 2019; de Souza Almeida Matos et al., 2019).